Why Amgen Hired An AI Head From Nike

Why Amgen Hired An AI Head From Nike

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations more efficient. But most of the best data scientists aren’t working in healthcare—at least not yet.

SES AI to Launch Its Material Discovery Software and Service Platform, Molecular Universe MU-0, Powered by Physics and AI, and Set to Transform Material Discovery in Battery Industry

WOBURN, Mass.--(BUSINESS WIRE)--Apr 10, 2025-

Recursion and Enamine launch targeted chemical libraries - Research & Development World

Navigating chemical libraries containing tens of billions of potential drug molecules presents a significant challenge in drug discovery. Seeking to streamline this process, Recursion (NASDAQ: RXRX), a clinical-stage TechBio company, and Enamine, an integrated discovery Contract Research Organisation (CRO), have announced a collaboration. Applying machine learning predictions from its Recursion OS platform, Recursion analyzed Enamine’s… The post…

Revolutionizing Molecule Design: How AI And MIT Research Are Transforming Medicines And Materials Development

Researchers from MIT and IBM have developed a multimodal AI system that combines large language models with graph-based models to design molecules more effectively, achieving a 35% success rate in generating valid synthesis plans compared to just 5% for existing methods.